HOLOGIC (HOLX) Company Report

Monteverde & Associates PC is investigating Hologic’s $13.4 billion sale to funds managed by Blackstone and TPG, under which shareholders will receive $76.00 per share in cash plus a contingent value right of up to $3.00 per share in two $1.50 payments.
The alert is offered at no cost or obligation, backed by a Top 50 securities class action firm based in New York City.
The firm is simultaneously probing related M&A deals for MidWestOne (0.3175 share exchange ratio), Nicolet Bankshares, and American Water’s merger with Essential Utilities (resulting in ~69% ownership).

Nov 21, 2025, 10:30 PM

Press Release

Hologic expands CE marking for Genius™ Digital Diagnostics

HOLX

Product Launch

Hologic’s Genius™ Digital Diagnostics System achieved expanded CE marking in the EU to image and review both cell and tissue specimens using whole slide imaging.
The upgrade allows European labs to unify their digital pathology workflows on a single platform, aiming to reduce operational costs and turnaround times.
The expansion includes new software features—remote support, LIS readiness and advanced review tools—to enhance diagnostic efficiency.
Whole slide imaging remains unavailable in the United States; commercialization details will be announced by country.

Nov 12, 2025, 1:11 PM

Press Release

Hologic announces Q4 2025 results

HOLX

Earnings

M&A

Guidance Update

Hologic reported Q4 revenue of $1,049.5 million, up 6.2% year-over-year; GAAP diluted EPS of $0.83, up 9.2%, and non-GAAP diluted EPS of $1.13, up 11.9%.
On October 21, 2025, Hologic agreed to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share.
By segment, Diagnostics revenue was $454.1 million (+2.4%), Breast Health revenue was $393.7 million (+4.8%), and Surgical revenue was $172.5 million (+10.2%).
Operating cash flow was $355.1 million in the quarter and cash and cash equivalents ended at $1.96 billion; the company has withdrawn its FY2026 guidance due to the pending acquisition.

Nov 3, 2025, 9:01 PM

8-K

Hologic reports Q4 2025 results

HOLX

Earnings

M&A

Hologic recorded $1.0495 B in Q4 2025 revenue, up 6.2% year-over-year, and delivered $1.13 non-GAAP diluted EPS, up 11.9%.
Non-GAAP operating margin expanded 120 bps to 31.2% in Q4 2025.
Organic revenue excluding COVID-19 assays reached $998.6 M, growing 6.2% on a constant-currency basis.
The company announced it will be acquired by Blackstone and TPG for $76 per share in cash plus a contingent value right of up to $3, with closing expected in H1 2026.
Hologic ended Q4 2025 with $2.2 B in cash and investments and a net leverage ratio of 0.4×, providing strategic flexibility.

Nov 3, 2025, 9:00 PM

Presentation

Hologic under scrutiny in sale to Blackstone and TPG

HOLX

M&A

Legal Proceedings

Takeover Bid

The Ademi Firm is investigating Hologic (Nasdaq: HOLX) for possible breaches of fiduciary duty in its proposed transaction with Blackstone and TPG.
Hologic shareholders are to receive $76 per share in cash plus a contingent value right of up to $3 per share, payable in two installments based on global Breast Health revenue targets in FY 2026 and 2027.
The deal agreement imposes a significant penalty on Hologic if it accepts a competing bid, potentially limiting alternative offers.
The investigation questions whether the Hologic board is fulfilling its fiduciary duties and highlights substantial insider benefits tied to the change of control.

Oct 21, 2025, 5:53 PM

Press Release

Hologic to be acquired by Blackstone and TPG

HOLX

M&A

Hologic entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG for $76 per share in cash plus a contingent value right of up to $3 per share, implying total consideration of up to $79 per share and an enterprise value of $18.3 billion.
The offer represents a 46% premium to Hologic’s closing stock price on May 23, 2025, the last full trading day before media reports of the transaction surfaced.
The transaction includes significant minority investments from the Abu Dhabi Investment Authority and GIC, is expected to close in the first half of calendar 2026 subject to stockholder and regulatory approvals, and will result in Hologic’s common stock being delisted from Nasdaq.
Concurrent with the deal announcement, Hologic suspended financial guidance for fiscal 2026 and will not hold any earnings calls while the transaction is pending.

Oct 21, 2025, 1:58 PM

8-K

Hologic gains FDA and CE clearance for rapid GI pathogen detection assays

HOLX

Product Launch

Hologic received FDA 510(k) clearance and CE marking in the EU for its Panther Fusion gastrointestinal bacterial and expanded bacterial assays, enabling rapid detection of pathogens such as Salmonella, Campylobacter, Shigella, and E. coli.
The assays offer customizable mini-panels that can be run together or separately, streamlining laboratory workflows by reducing labor and speeding time to diagnosis versus traditional culture and microscopy methods.
Testing is performed on Hologic’s Panther Fusion system, an add-on to the fully automated Panther platform, demonstrating seamless integration with existing laboratory automation.
This regulatory approval follows Hologic’s strategic $159 million acquisition of Diagenode in 2021, which expanded the company’s proprietary real-time PCR testing portfolio.

Oct 2, 2025, 4:50 PM

Morningstar

Hologic amends and refinances credit facilities

HOLX

Debt Issuance

On July 15, 2025, Hologic entered into Refinancing Amendment No. 4 to its Amended and Restated Credit and Guaranty Agreement, replacing its existing term and revolving loans with $1,169,000,000 of 2025 Refinancing Term Loans and $1,000,000,000 of Revolving Credit Commitments, with Bank of America, N.A. as Administrative Agent.
The amendment introduces customary affirmative and negative covenants, including maintenance of a minimum 3.00× Interest Coverage Ratio and maximum Total Net Leverage Ratios of 5.00:1.00 (stepping down to 4.50:1.00 over time), plus mandatory prepayment provisions on asset sales, debt issuances and insurance recoveries.
The associated Pledge and Security Agreement was amended to secure the refinanced obligations with substantially all assets of Hologic and its Subsidiary Guarantors.
The amendment is filed as Exhibit 10.1 to Hologic’s Form 8-K, dated July 18, 2025.

Jul 18, 2025, 12:00 AM

8-K

Hologic Special Call Addresses Guidance Adjustments and Strategic Investments

HOLX

Guidance Update

M&A

Share Buyback

Q2 guidance update: Hologic delivered revenue and EPS at the high end of its guidance range, though it adjusted its full-year EPS outlook downward by $0.10 due to anticipated tariff headwinds of $20-25 million per quarter related to Costa Rica manufacturing.
US policy and domestic strategy: The company clarified that recent USPSTF guidelines supporting co-testing have eased concerns over cervical cancer screening tests, and its focus remains on leveraging its strong domestic presence, particularly in diagnostics, where favorable FX helped offset China headwinds.
Capital deployment focus: Hologic is aggressively deploying free cash flow, with over $1.5 billion in cash and more than $700 million deployed in share repurchases, while also pursuing strategic M&A opportunities with recent acquisitions like Gynesonics and Endomag.
Product and technology expansion: The firm continues to expand its Panther Fusion platform, enhancing its multiplexing capabilities in respiratory and STD testing, thereby reinforcing its dominant market position in these segments.

May 20, 2025, 1:31 PM

Transcript

Hologic Inc Q2 2025 Earnings & Financial Results Announced

HOLX

Earnings

Guidance Update

Share Buyback

Revenue Acceleration/Inflection

Reported Q2 revenue of $1.005 billion (organic $980.0M), with GAAP diluted EPS of ($–0.08) and non-GAAP EPS of $1.03, ending the quarter at the high end of guidance .
Achieved strong operating performance with GAAP operating margin (0.7%) and non-GAAP operating margin 30.0%, alongside a reduction in net leverage to 0.8x .
Segment Performance: Diagnostics drove growth, the Skeletal business improved with easing supply constraints, while Breast Health revenue declined due to softer gantry sales .
Generated $169.5 million in operating cash flow with robust liquidity and executed a strategic share repurchase of 3.0 million shares for $200 million .
Provided updated guidance with Q3 revenue expected between $1 billion and $1.01 billion, and full-year 2025 guidance between $4,050–$4,100M in revenue with non-GAAP EPS of $4.15–$4.25 .

May 1, 2025, 8:31 PM

Transcript Presentation 8-K

Earnings Transcripts

Quarterly earnings call transcripts for HOLOGIC.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Stephen P. MacMillan say about margins?What are HOLOGIC's strategic priorities?How is HOLOGIC positioned vs competitors?How did HOLOGIC do last quarter?

Let Fintool AI Agent track HOLOGIC's earnings for you

Get instant analysis when filings drop